Peter J. Dailey

TL;DR: Estimates of the numbers of infected cells and the virus they could produce are consistent with the quantities of virus that have been detected in the bloodstream, and the cellular sources of virus production and storage in lymphoid tissues can now be studied over the course of infection and treatment.

TL;DR: This study shows that SIV genital infection and disease course are enhanced by subcutaneous implants containing progesterone when compared with the rate of vaginal transmission in the follicular phase.

TL;DR: It is concluded that this multiply deleted SIV is pathogenic and that human AIDS vaccines built on similar prototypes may cause AIDS.

TL;DR: These studies demonstrate that sequential, phenotypic and antigenic variants represent viruses that have become increasingly fit for replication in the host and support the hypothesis that emerging variants have increased pathogenicity and drive disease progression in SIV and HIV infection.

TL;DR: Results indicate that host responses capable of reducing the viral load in plasma and lymph nodes were induced as early as 5 weeks after immunization with SIVmac239Δnef, while more potent protection developed between 10 and 15 weeks.